Editing Insomnia (section)

==== Orexin antagonists ====
[[Orexin receptor antagonist]]s are a more recently introduced class of sleep medications and include [[suvorexant]], [[lemborexant]], and [[daridorexant]], all of which are FDA-approved for treatment of insomnia characterized by difficulties with [[sleep onset]] and/or sleep maintenance.<ref name="pmid35043499">{{cite journal | vauthors = Jacobson LH, Hoyer D, de Lecea L | title = Hypocretins (orexins): The ultimate translational neuropeptides | journal = J Intern Med | volume = 291| issue = 5| pages = 533–556| date = January 2022 | pmid = 35043499 | doi = 10.1111/joim.13406 | s2cid = 248119793 | url = }}</ref><ref name="prescribing info">{{cite web |url=http://www.merck.com/product/usa/pi_circulars/b/belsomra/belsomra_pi.pdf |title=Highlights of prescribing information |url-status=live |archive-url=https://web.archive.org/web/20140912065432/http://www.merck.com/product/usa/pi_circulars/b/belsomra/belsomra_pi.pdf |archive-date=12 September 2014 }}</ref> They are oriented towards blocking signals in the brain that stimulate wakefulness, therefore claiming to address insomnia without creating dependence. There are three [[Orexin antagonist|dual orexin receptor (DORA)]] drugs on the market: [[Suvorexant|Belsomra]] ([[Merck & Co.|Merck]]), [[Lemborexant|Dayvigo]] ([[Eisai (company)|Eisai]]) and [[Daridorexant|Quviviq]] ([[Idorsia]]).<ref name="Dunleavy"/>